High-resolution melting curve analysis (HRM) of polymerase chain reaction (PCR) amplicons has been described as a fast, cheap, and reliable closed-tube method of genotyping with no need for labeled primers or labeled probes. We adapted this melting analysis assay for the detection of the most common nonfunctional alleles of cytochrome P-450 (CYP) 2D6 in the Caucasian population that affect the metabolism of many commonly used drugs. We used this method to genotype 91 patients under paroxetine therapy. The presence and the constitution of the most common single-nucleotide polymorphisms (1846G>A, 2988G>A, 100C>T, 2549delA, 2615_2617delAAG, and 1707delT) in poor and intermediate metabolizers from the Caucasian population were detected in short amplicons (≤148 bp). After fluorescence normalization, the wild-type, homozygous, and heterozygous samples were easily distinguishable from each other by their specific melting curve shape. A total of 92.6% of the 1846G>A heterozygotes, 96% of the 100C>T heterozygotes, and 100% of the 2988G>A, 2549delA, 2615_2617delAAG, and 1707delT heterozygotes have been correctly distinguished from the wild types. One hundred percent of all the homozygotes in this group of patients have been detected without any error. HRM of short amplicons is a simple tool for effective, rapid, and reliable CYP2D6 genotyping that does not require real-time PCR, labeled probes, processing or any separations after PCR. The reaction is performed in a closed-tube system and is highly specific and sensitive. We proved that this technique is highly reliable for use in routine diagnostics.

Department of Applied Neuroscience Faculty of Medicine Central European Institute of Technology Brno Czech Republic

Zobrazit více v PubMed

Clin Chem. 2007 Jul;53(7):1377-80 PubMed

BMC Cancer. 2006 Dec 21;6:295 PubMed

Assay Drug Dev Technol. 2002 Nov;1(1 Pt 1):49-59 PubMed

Clin Chem. 2004 Oct;50(10):1748-54 PubMed

Am J Clin Pathol. 2005 Sep;124(3):330-8 PubMed

Clin Pharmacol Ther. 1992 Jan;51(1):12-7 PubMed

Prague Med Rep. 2006;107(4):383-93 PubMed

Clin Chem. 2005 Jul;51(7):1295-8 PubMed

Hum Mutat. 2003 Dec;22(6):476-85 PubMed

Clin Chem. 2003 Jun;49(6 Pt 1):853-60 PubMed

Eur J Clin Pharmacol. 1994;47(3):221-5 PubMed

Am J Hum Genet. 1980 May;32(3):314-31 PubMed

Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1240-7 PubMed

Clin Chem. 2002 Sep;48(9):1412-7 PubMed

Ther Drug Monit. 2011 Aug;33(4):425-32 PubMed

FEBS Lett. 1996 Aug 19;392(1):30-4 PubMed

Curr Opin Obstet Gynecol. 2008 Dec;20(6):550-6 PubMed

Anal Biochem. 2005 Nov 1;346(1):167-75 PubMed

J Mol Diagn. 2008 Sep;10(5):424-34 PubMed

Methods Mol Biol. 2008;448:21-30 PubMed

Clin Chem. 2004 Jul;50(7):1156-64 PubMed

Pharmacogenomics J. 2005;5(1):6-13 PubMed

Anal Biochem. 2000 Apr 10;280(1):103-10 PubMed

J Natl Cancer Inst. 2005 Jan 5;97(1):30-9 PubMed

Proc Natl Acad Sci U S A. 1980 Aug;77(8):4420-4 PubMed

Pharmacogenomics. 2007 Jun;8(6):597-608 PubMed

Pharmacol Ther. 2007 Dec;116(3):496-526 PubMed

Am J Clin Pathol. 2006 Apr;125(4):584-91 PubMed

Clin Biochem. 2009 Aug;42(12):1308-16 PubMed

Clin Chem. 1997 Oct;43(10):1984-6 PubMed

Hum Mutat. 2008 May;29(5):757-64 PubMed

Clin Biochem. 2008 Feb;41(3):162-6 PubMed

Exp Mol Pathol. 2008 Aug;85(1):50-8 PubMed

Naunyn Schmiedebergs Arch Pharmacol. 2004 Jan;369(1):23-37 PubMed

Am J Clin Pathol. 2006 Oct;126(4):608-15 PubMed

Curr Pharm Des. 2007;13(2):241-50 PubMed

Genet Test. 1999;3(2):201-5 PubMed

Biotechniques. 2005 Oct;39(4):577-82 PubMed

Clin Chem. 2005 Jul;51(7):1291-5 PubMed

Anal Biochem. 2008 Mar 15;374(2):396-404 PubMed

Nucleic Acids Res. 2008 Jun;36(10):3401-8 PubMed

Gen Physiol Biophys. 2003 Mar;22(1):103-13 PubMed

Cell Mol Life Sci. 2001 May;58(5-6):737-47 PubMed

Nat Protoc. 2007;2(1):59-66 PubMed

Electrophoresis. 1999 Jun;20(6):1258-65 PubMed

Am Fam Physician. 2007 Oct 15;76(8):1179-82 PubMed

Clin Chem. 2005 Oct;51(10):1770-7 PubMed

Am J Clin Pathol. 2006 Apr;125(4):625-33 PubMed

Am J Hum Genet. 1997 Feb;60(2):284-95 PubMed